Recombinant Anti-Idiotypic Antibodies for Antibody Drug Development

Antibody drug development projects require tools for monitoring the concentration of these drug candidates in patient samples and standards for measuring anti-drug antibodies (ADA). We have used the HuCAL® recombinant antibody technology for fast development of fully human Fab and IgG anti-idiotypic (anti-ID) antibodies binding specifically and with high affinity to well-known drugs like Herceptin®, Avastin®, Rituxan®, Remicade®, Humira® and others. The HuCAL phage display approach allows for the generation of inhibitory and non-inhibitory anti-idiotypic antibodies as well as development of antibodies against drug-target complexes. These reagents are used as fully human reference standards in ADA assays and for the development of PK assays for analysis of non-clinical and clinical samples